Clinical Pharmacokinetics of Vinorelbine

Abstract

Vinorelbine (5'-noranhydrovinblastine) is a recently developed semisynthetic anticancer drug which belongs to the Catharanthus alkaloid family. Its mechanism of action is only partially known but it is assumed that it acts, like vinblastine and vincristine, as an antimicrotubule agent arresting cell division in mitosis. Clinically, vinorelbine has mainly shown activity in the treatment of advanced non-small-cell lung cancer and the treatment of metastatic breast cancer. Early pharmacokinetic data were obtained with radioactive assays (radio-immunoassay or 3H-labelled vinorelbine), then with more selective high performance liquid chromatographic techniques. Vinorelbine is usually administered intravenously but there has also been some experimentation with an oral formulation. The bioavailability of a liquid filled gelatin capsule ranges between 12 and 59% with a mean value of 27% [standard deviation (SD) 12%]. Vinorelbine is rapidly absorbed with peak serum concentration reached within 2 hours. In vitro, vinorelbine is mainly distributed into the blood cells, especially platelets (78%) and lymphocytes (4.8%) The unbound blood fraction is around 2%. In lung tissue vinorelbine concentrations are much higher than in serum, by up to 300-fold 3 hours after administration. Little is known about the biotransformation of vinorelbine. Desacetylvinorelbine is considered to be a minor metabolite and is only found in urine fractions, representing 0.25% of the injected dose. Urinary excretion of vinorelbine is low, accounting for less than 20% of the dose. Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively. The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg. Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)]. This could be due to the greater specificity of the chromatographic method. Vinorelbine has been administered by continuous intravenous infusion over 4 days. Steady-state was reached and the concentrations obtained were above the in vitro IC50 (concentration of drug causing 50% inhibition). The effect of liver disease on vinorelbine pharmacokinetics has been studied in patients with breast cancer. Patients with massive secondary liver disease had a lower systemic clearance than those who have no liver disease or a lesser invasion. In children, vinorelbine seems to display a shorter t1/2 (14.7 hours) than that found in adults. In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)]. Vinorelbine is often co-administered with cisplatin in the treatment of advanced non-small-cell lu...

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

“…Docetaxel plasma level (C max ), AUC and Cl did not appear to be affected when VNB preceded DTX (protocol A). However, the pharmacokinetic constants extrapolated during the terminal phase of C/t plasma level, such as V z , K e and t 1/2 (calculated following the KINETICA algorithm), varied significantly between protocol A and protocol B, the former being similar to those found in the literature (26). These data are similar to those observed in a group of heavily pretreated patients (mostly with advanced head and neck cancer) submitted to the same regimen (27).…”

A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

“…11,12 Vinorelbine is a semisynthetic Vinca alkaloid which inhibits microtubule synthesis, 13 whereas gemcitabine is a nucleoside analog of deoxycytidine which undergoes intracellular activation. 14 The agents have differing mechanisms for activity and little overlapping toxicity, and can both be administered in the outpatient setting via short intravenous infusions.…”

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

“…2A). The model is based on established pharmacodynamics and known effects of each of the agents [21][22][23][24][25][26][27][28][29] on the cell cycle for 10 tumor types [31][32][33][34][35][36][37][38] and for erythroblasts 39 (erythroblasts have the highest proliferative index of marrow (Fig. 2B).…”

“…f(t) is a probability of effect based on the individual [16][17][18][19][20] or combined [21][22][23][24][25][26][27][28][29] effects of temsirolimus, topotecan, and bortezomib which have been previously described.…”